2) Synergistic effects of CDK9 inhibitors with venetoclax, temozolomide, TRAIL, Nutlin-3a, cisplatin, and JQ1 on leukemia and solid tumor cells have been explored, largely with venetoclax, and promising results have been reported (Table 2). The gene discussed is CDK9; the disease is leukemia.